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INTRODUCTION
The majority of studies devoted to gastrointestinal side effects after radiotherapy for prostate cancer are focused on rectal bleeding, faecal incontinence and overall acute gastrointestinal toxicity. These studies often resulted in the quantification of dose-volume effects for organs-at-risk (primary the rectum) and led to the development of predictive models for radiotherapy-induced toxicity, which sometimes including clinical risk factors [1] [2] [3] .
Nevertheless, chronic radioinduced rectal syndrome includes other symptoms [4] , such as urgency, increased stool frequency and rectal pain. There is insufficient knowledge on the incidence of these morbidities and on their relationship with the dose distribution in the rectum and in the anal canal. This is mainly due to their being relatively rare effects; there is difficulty in identifying radiation as the cause of these impairments in an ageing population and the lack of controlled questionnaire-based prospective scoring describing the pre-radiotherapy baseline situation.
Nevertheless, these symptoms may clearly have a non-negligible impact on the quality of life (QoL) of long-surviving patients [5] and consequently deserve attention.
The availability of a large dataset consisting of a pooled population from two large prospective trials [6, 7] that represents more than one thousand patients with a minimum of 3 years of follow-up allowed us to focus on these often neglected gastrointestinal side effects: stool frequency and rectal pain.
The two cohorts were treated at different hospitals, with different dose levels, with different radiotherapy techniques, in different countries and in different time frames. As a consequence, current pooled population presented with a wide variety of dosimetric and clinical parameters, with the potential to reach sufficient statistical power to assess main associations between the selected rare side effects and clinical/dosimetric features. The aim of current study was to develop multivariable logistic (MVL) regression models for both the above mentioned toxicity endpoints. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 4
MATERIALS and METHODS

Patient population
A pooled population from two high quality multicentre prospective trials on radiotherapy for prostate cancer was created.
a. Airopros 0102: a prospective multicentre observational trial specifically designed to evaluate dosimetric/clinical factors associated with acute and late rectal syndrome symptoms after radical radiotherapy for prostate cancer (details can be found in [6,8-10]) b) TROG03.04 RADAR: a prospective multicentre randomized trial designed to determine whether adjuvant androgen suppression, bisphosphonates and radiation dose escalation might improve oncologic outcomes in localized prostate cancer (details in [7, [11] [12] [13] [14] [15] ). In this trial, d toxicity was prospectively scored as a secondary endpoint.
All patients were treated with radical three-dimensional conformal radiotherapy (3DCRT) in the period Co-morbidities (diabetes, hypertension, cardiovascular diseases, and the presence of haemorrhoids), previous abdominal/pelvic surgery, use of drugs and previous/concomitant loco-regional diseases were evaluated with a specifically designed questionnaire administered prior to radiotherapy. Information on the quality and duration of the hormonal therapy was also recorded when prescribed to the patient. These clinical information was collected from both trial in a similar way.
Other information concerning the volume definition, planning and treatment modalities as well as the distribution of the main clinical parameters of the two populations have previously been reported in detail [6] [7] [8] 11] . Of particular importance is the delineation of the anorectum: an anatomically based definition (from the anus to the point where the rectum turns into the sigmoid) was used by the participating centres in both trials. This definition was previously found to be sufficiently robust for the aims of dose-volume studies. The dose-volume histogram (DVH) of the solid rectum was considered.
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Gastrointestinal symptoms were determined according to the LENT/SOMA (Late Effects of Normal Tissue/Subjective, Objective, Management and Analytic) scoring systems for late radiation morbidity.
Late rectal pain and stool frequency were analysed in the current study.
Rectal pain was considered as a peak toxicity and grade≥2 (i.e., intermittent & tolerable OR persistent & intense pain) was scored as a toxicity event. We defined a late event if it occurred in the time frame 6-36 months after the end of 3DCRT. For stool frequency, we chose a longitudinal definition; mean stool frequency was defined as the average score during the 3-year period after RT. Patients with at least three out of six follow-up points were included in this analysis. An average mean stool frequency>1 was arbitrarily considered as the endpoint as it selects those patients with persistent symptoms (i.e., patients who on average evacuated >2 times/day), more likely to be those whose symptoms are actually due to radiotherapy.
Longitudinal definitions of toxicity were already considered for faecal incontinence by Gulliford et al. [16] and Fiorino et al. [17] , which suggested that the longitudinal approach is more appropriate in describing both the severity and persistence of moderate symptoms that are very important for QoL and the social activities of patients.
The baseline questionnaire was used to exclude patients with symptoms that were already present before radiotherapy, while the end of treatment evaluation was defined acute gastrointestinal toxicity following the RTOG/EORTC definition.
Development of multivariable logistic models
Univariable logistic regression was used to determine the association between toxicity and clinical/dosimetric/treatment related factors.
The rectal dose-volume histogram (DVH) was reduced to the Equivalent Uniform Dose (EUD).
The value of the rectum volume parameter n for the two considered toxicity endpoints was determined through a sensitivity analysis: a set of EUDs were computed for a set of n-values ranging from 0 to 1 in 0.05 steps. These EUDs were inserted in univariate logistic models and n-value maximizing log likelihood (LLH) was chosen as the most suitable.
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The goodness-of-fit was determined through the Hosmer-Lemeshow (HL) test and the calibration plot (slope coefficient and R 2 ).
All statistical analyses were performed using KNIME software (KNIME GmbH, Germany) coupled with R software (www.r-project.org).
RESULTS
Patient characteristics
The merged dataset consisted of 1337 patients. A total of 1122 (445 patients from Airopros0102 and 677 from TROG 03.04 RADAR) with complete clinical and dosimetric information and a minimum follow up of 3 years were considered for analysis. Table 1 shows the characteristics of the patients included in the analysis. The two populations were significantly different for most clinical/treatment related parameters. Notably, all TROG 03.04 RADAR patients received neoadjuvant/adjuvant hormone therapy and irradiation of seminal vesicles, whereas irradiation of the pelvic nodes was not allowed in this trial.
1122 patients were included in the analysis of stool frequency (i.e., patients with no baseline symptoms and with at least 3 follow-up points in 3 years), while 677 were handled for rectal pain.
Toxicity rates were as follows: Multivariable model for late rectal pain grade≥2
As explained before, for modelling of late rectal pain, only the TROG 03.04 RADAR population was considered (677 patients, 21/677 toxicity events).
The presence of hormone therapy and irradiation of seminal vesicles and lymph nodes could not be considered as covariates in this population due to the previously explained homogeneity of the patients with respect to these factors.
Details on the univariate analysis including clinical risk factors are reported in the supplementary materials. Figure 4 shows the probability of late rectal pain grade≥2 as a function of EUD and the presence of grade≥2 acute gastrointestinal toxicity. Observed toxicity rates are reported together with model curves.
DISCUSSION
The current scientific knowledge considers radioinduced side effects as being associated with a large number of clinical/dosimetric factors that differ for each individual patient. Inferring these multifaceted models, including dosimetric and clinical features, directly from the current mechanistic radiobiological understanding is not a feasible approach, due to the intrinsically too complex nature of the involved mechanisms. For this reason, models developed in recent years have been derived from the exploration of clinical observations of large prospectively collected populations. These data-driven models aim to provide a phenomenological description of a complex situation and give indications of aspects that could be optimized to limit toxicity in future patients [18] .
The availability of a large pooled population of patients treated with radical radiotherapy for prostate cancer, objective evaluation of baseline function and a long prospective follow-up allowed analysis of less common gastrointestinal symptoms (stool frequency and rectal pain) and the development of data-driven models for these types of toxicities. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9 Late stool frequency was described using a longitudinal definition (mean frequency>1 in the first 3 years after the end of radiotherapy. This choice is crucial as endpoints based on peak toxicity have a high probability to be associated to causes other than radiotherapy, as previously discussed [17] .
This toxicity was found to be associated with mean rectal dose (EUD calculated with n=1)) and the presence of cardiovascular disease (OR=1.78). Previously published results on this toxicity endpoint are sparse and include slightly different definitions/organs at risk than the present work. Nevertheless there is general agreement on the importance of mean rectal dose/large volumes included in the medium range of doses (30-50 Gy, see figure 1 ). In a previously published analysis on the TROG 03.04 RADAR population, Ebert et al [12] found significant association between stool frequency defined as peak toxicity and the mid-to-low dose range (8-58 Gy) in the anal canal and with mid-to-high doses in the anorectum. Defraene et al [19] presented a model for incidence of severe frequency (>6 bowel movements/day) including mean dose, while Schaake et al. [20] highlighted the association between anorectal side effects and different anatomical substructures within and around the rectum. Toxicity scoring was in this case based on the CTCAE scale (defined as incidence and not longitudinally). They found that stool frequency was significantly associated with the volume of the levator ani receiving more than 40 Gy and with the volume of coccygeal muscle irradiated at more than 45 Gy. The significant volume parameters for EUD calculation were in the range 0.5-1.
When considering clinical factors acting as dose-response modifiers, cardiovascular diseases were already found to be a risk factor for enhanced toxicity for a number of other late gastrointestinal endpoints by previously published trials [19, 21] . Patients harbouring these types of comorbidities should be granted special attention, optimization and/or prophylactic treatment.
Late rectal pain was found to be associated with rectal volumes receiving 30-50 Gy (see Figure 1 ) and with an EUD calculated with n=0.35. Patients exhibiting grade≥2 acute gastrointestinal toxicity were at a higher risk of late moderate/severe pain (OR=4.2). This could be related to a consequential effect between acute injury and late pain and to a possibly enhanced radiosensitivity of some patients who report worse acute injury and more severe late toxicity. Patients showing intense acute reactions might be require a stricter follow up for sudden treatment and mitigation of this type of morbidity. A previous analysis of the TROG 03.04 RADAR population referred to rectal pain of any grade [12] was not able to find a dose-response relationship. The inclusion of grade 1 pain (occasional & mild pain) probably blurred the relationship between this endpoint and doses. 
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The recent work by Schaake et al. [20] was the only other study that considered the rectal pain endpoint, but they were not able to find any associations between pain and dosimetric/clinical factors.
Findings from analysis of stool frequency and rectal pain are coherent with what was already found in a number of studies when modelling late fecal incontinence [16, 17, 19] . For all these symptoms there is a relevant indication on the role of mid-range doses to large volumes of the anorectum, which is markedly different from the dose-volume relationship for rectal bleeding, which is related to low volumes receiving high doses. This parallel-like behavior of the anorectum could be biologically related to radioinduced fibrosis and consequent rectal stiffness due to large volumes receiving doses around 30-50
Gy. An interesting study on investigation of the patophysiology of anorectal radioinduced toxicity considered the relationship between anal/rectum pressures, rectal capacity and sensory functions and side effects [22, 23] . They found that radioinduced rectal stiffness seems associated with rectal wall dysfunction and toxicity.
CONCLUSIONS
Two models were developed to describe the relationship between stool frequency/rectal pain and dosimetric/clinical risk factors.
In a large pooled population that included more than 1000 patients from two prospective trials, the mean rectal dose was found to be associated persistently increased stool frequency in the first three years after radiotherapy.
Large volumes of the rectum irradiated to mid-range doses (30 to 50 Gy) were found to be related to both stool frequency and rectal pain (for this latter endpoint, EUD calculated with the volume parameter n=0.35 gave the best dose-response relationship).
Cardiovascular diseases and acute gastrointestinal toxicity were significant risk factors the two symptoms.
All of these findings are coherent with previous modelling of late faecal incontinence [16, 17, 19] , suggesting that the sparing of the ano-rectum from low-to-mid-range doses may reduce the incidence of these symptoms, having a high impact on the QoL of long-surviving patients.
Use of intensity modulated radiotherapy and of stereotactic techniques, with their possibility of reducing low-to-mid doses over large volumes, has the potential to avoid these toxicities. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11
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